The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussion could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Biomedical Library and Informatics Review Committee.

Date: June 16–19, 2003.

Time: June 18, 2003, 8:30 a.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 38, Board Room, 8600 Rockville Pike, Bethesda, MD 20892.

Time: June 19, 2003, 8 a.m. to 12:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 38, Board Room, 8600 Rockville Pike, Bethesda, MD 20892.

Contact Person: Merlyn M. Rodrigues, MD, PhD, Scientific Review Adm., National Library of Medicine, Extramural Programs, 6705 Rockledge Drive, Suite 301, Bethesda, MD 20894.

Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHJ.


LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 03–9915 Filed 4–21–03; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: The Use of the Domain-Swapped Dimer of Cyanovirin (deltaQ50–CVN) in a Topical Microbicide To Prevent the Transmission of HIV and Other Sexually Transmitted Diseases

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the granting of an exclusive license worldwide to practice the invention embodied in:


DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 23, 2003, will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Sally Hu, Ph.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3300. Telephone: (301) 435–5060; Facsimile: (301) 402–0220, e-mail: hu@od.nih.gov.

SUPPLEMENTARY INFORMATION: The patent application describes a novel protein, obligate domain-swapped dimer of Cyanovirin-N (CVN), discovered by Dr. Carole A. Bewley at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The obligate domain-swapped dimer of Cyanovirin-N (CVN) displays enhanced anti-HIV activity relative to the wild-type CVN monomer and offers a great advantage over wild-type CVN because it is extremely easy to purify large quantities to greater than 98% homogeneity. So, it may open the possibility that an effective drug treatment for the human immunodeficiency virus (HIV) could reach underdeveloped countries.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to compositions, devices and methods for the prevention of infection by HIV and other sexually transmitted pathogens, topically, but not systemically, utilizing the obligate domain-swapped dimer cyanovirin-N, anti-HIV mutants of the obligate domain-swapped dimer cyanovirin-N, and anti-HIV fragments of both, but excluding pegylated the domain-swapped dimer cyanovirin-N, pegylated anti-HIV mutants of the dimer cyanovirin-N and pegylated anti-HIV fragments of both.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.


Steven M. Ferguson,
Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 03–9925 Filed 4–21–03; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: The Systemic In Vivo Use of the Domain-Swapped Dimer of Cyanovirin (DeltaQ50–CVN) as a Prophylactic or Therapeutic Against HIV and Enveloped Viruses That Cause Hemorrhagic Fever; the Ex Vivo Use of the Domain-Swapped Dimer of Cyanovirin (DeltaQ50–CVN) To Remove or Inactivate HIV in Fluid Samples

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the granting of an exclusive license worldwide to practice the invention embodied in:


DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before June 23, 2003 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Sally Hu, Ph.D., M.B.A.,
Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–5606; Facsimile: (301) 402–0220, e-mail: hus@od.nih.gov.

SUPPLEMENTARY INFORMATION: The patent application describes a novel protein, obligate domain-swapped dimer of Cyanovirin-N (CVN), discovered by Dr. Carole A. Bewley at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The obligate domain-swapped dimer of Cyanovirin-N (CVN) displays enhanced anti-HIV activity relative to the wild-type CVN monomer and offers a great advantage over wild-type CVN because it is extremely easy to purify large quantities to greater than 98% homogeneity. So, it may open the possibility that an effective drug treatment for the human immunodeficiency virus (HIV) could reach underdeveloped countries.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to:

1. Compositions, devices and methods for the prevention and treatment of HIV infection and infections caused by enveloped viruses causing hemorrhagic fever, systemically, but not topically, utilizing obligate domain-swapped dimer of Cyanovirin-N, anti-HIV mutants of obligate domain-swapped dimer of Cyanovirin-N, and anti-HIV fragments of both;

2. Compositions, devices and methods for the ex vivo removal or inactivation of HIV from fluid samples, utilizing obligate domain-swapped dimer of Cyanovirin-N, anti-HIV mutants of obligate domain-swapped dimer of Cyanovirin-N, and anti-HIV fragments of both;

but excluding pegylated obligate domain-swapped dimer of Cyanovirin-N, pegylated anti-HIV mutants of obligate domain-swapped dimer of Cyanovirin-N and pegylated anti-HIV fragments of both.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.


Steven M. Ferguson,
Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 03–9924 Filed 4–21–03; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

Open Meeting, Advisory Committee for the National Urban Search and Rescue Response System


ACTION: Notice of open meeting.

SUMMARY: In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C. App.), we, EP&R, announce the following committee meeting:

Name: National Urban Search and Rescue System Advisory Committee.

Date of Meeting: April 30–May 1, 2003.

Place: Holiday Inn Capital, 550 C Street, Apollo Room, Washington, DC 20024.

Time: April 30: 8 a.m.–4 p.m. May 1: 8 a.m.–4 p.m.

Proposed Agenda: The Committee will receive a program update that will address the status of ongoing program activities, including recent training and exercises. The committee will consider current and future program requirements and will make recommendations for budget allocations and requests for Fiscal Years 2004 and 2005. The Committee will also discuss urban search and rescue task force operational status and transportation issues. The Committee will review the current status of proposed urban search and rescue regulations and system documentation revisions. Finally, the committee will review priorities for its subordinate working groups for the remainder of Fiscal Year 2003.

The meeting will be open to the public, with approximately 20 seats available on a first-come, first-served basis. All members of the public interested in attending should contact Michael Tamillow at 202–646–3498.

We will prepare minutes of the meeting and will make them available for public viewing at the Emergency Preparedness and Response Directorate, Preparedness Division, Urban Search and Rescue (US&R), 500 C Street, SW., Room 326, Washington, DC 20472. Copies of the minutes will be available upon request 30 days after the meeting.


Michael D. Brown,
Undersecretary, Emergency Preparedness and Response.

[FR Doc. 03–9868 Filed 4–21–03; 8:45 am]
BILLING CODE 6718–06–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Availability of an Agency Draft Recovery Plan for Five Freshwater Mussels—Cumberland Elktoe (Alasmidonta atropurpurea), Oyster Mussel (Epioblasma capsaeformis), Cumberlandian Combshell (Epioblasma brevidens), Purple Bean (Villosa perpurpurea), and Rough Rabbitsfoot (Quadrula cylindrica strigillata)—for Review and Comment

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of document availability and public comment period.

SUMMARY: We, the Fish and Wildlife Service, announce the availability of the agency draft recovery plan for five freshwater mussels—Cumberland elktoe (Alasmidonta atropurpurea), oyster mussel (Epioblasma capsaeformis), Cumberlandian combshell (Epioblasma brevidens), purple bean (Villosa perpurpurea), and rough rabbitsfoot (Quadrula cylindrica strigillata). These species are endemic to the Cumberland and Tennessee River systems in Alabama, Kentucky, Mississippi, Tennessee, and Virginia. Recent research has greatly increased our understanding of the ecology of these species. The agency draft recovery plan includes specific recovery objectives and criteria to be met in order to downlist these mussels to threatened status or delist them under the Endangered Species Act of 1973, as amended (Act). We solicit review and comment on this agency draft recovery plan from local, State, and Federal agencies, and the public.

DATES: In order to be considered, we must receive comments on the draft recovery plan on or before June 23, 2003.